JP2025500944A5 - - Google Patents
Info
- Publication number
- JP2025500944A5 JP2025500944A5 JP2024537033A JP2024537033A JP2025500944A5 JP 2025500944 A5 JP2025500944 A5 JP 2025500944A5 JP 2024537033 A JP2024537033 A JP 2024537033A JP 2024537033 A JP2024537033 A JP 2024537033A JP 2025500944 A5 JP2025500944 A5 JP 2025500944A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- region
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291910P | 2021-12-20 | 2021-12-20 | |
| US63/291,910 | 2021-12-20 | ||
| PCT/US2022/082021 WO2023122588A2 (en) | 2021-12-20 | 2022-12-20 | Egfr-cmet–targeted compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500944A JP2025500944A (ja) | 2025-01-15 |
| JP2025500944A5 true JP2025500944A5 (https=) | 2025-12-24 |
Family
ID=86903719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537033A Pending JP2025500944A (ja) | 2021-12-20 | 2022-12-20 | ＥＧＦＲ－ｃＭＥＴ標的化合物及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250121104A1 (https=) |
| EP (1) | EP4452954A2 (https=) |
| JP (1) | JP2025500944A (https=) |
| KR (1) | KR20240125970A (https=) |
| CN (1) | CN118765273A (https=) |
| AR (1) | AR128052A1 (https=) |
| AU (1) | AU2022419564A1 (https=) |
| CA (1) | CA3244030A1 (https=) |
| CL (1) | CL2024001832A1 (https=) |
| CO (1) | CO2024008733A2 (https=) |
| CR (1) | CR20240254A (https=) |
| IL (1) | IL313333A (https=) |
| MX (1) | MX2024007596A (https=) |
| TW (1) | TW202333799A (https=) |
| WO (1) | WO2023122588A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4577527A1 (en) * | 2022-08-22 | 2025-07-02 | Abdera Therapeutics Inc. | Vhh antibody dota conjugates |
| AU2024323801A1 (en) * | 2023-08-14 | 2026-03-19 | Minghui Pharmaceutical (Hangzhou) Limited | Anti-c-met nanobody and use thereof |
| CN118085101A (zh) * | 2024-03-01 | 2024-05-28 | 烟台蓝纳成生物技术有限公司 | 一种二价双特异性抗体、抗体偶联核素药物及其应用 |
| CN120682361A (zh) * | 2024-03-22 | 2025-09-23 | 康源博创生物科技(北京)有限公司 | 一种多肽及其用于构建包含共同轻链的双特异性抗体中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7090204B2 (ja) * | 2018-07-19 | 2022-06-23 | イーライ リリー アンド カンパニー | 免疫チェックポイントを標的とする二重特異性抗体 |
| CN114945594B (zh) * | 2019-12-23 | 2024-11-26 | 株式会社Lg化学 | 抗lilrb1抗体及其用途 |
| KR20220157464A (ko) * | 2020-03-23 | 2022-11-29 | 퓨전 파마슈티칼즈 인크. | Fgfr3-표적화된 방사선면역접합체 및 그의 용도 |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
-
2022
- 2022-12-20 CR CR20240254A patent/CR20240254A/es unknown
- 2022-12-20 US US18/721,647 patent/US20250121104A1/en active Pending
- 2022-12-20 IL IL313333A patent/IL313333A/en unknown
- 2022-12-20 MX MX2024007596A patent/MX2024007596A/es unknown
- 2022-12-20 JP JP2024537033A patent/JP2025500944A/ja active Pending
- 2022-12-20 CA CA3244030A patent/CA3244030A1/en active Pending
- 2022-12-20 KR KR1020247024103A patent/KR20240125970A/ko active Pending
- 2022-12-20 WO PCT/US2022/082021 patent/WO2023122588A2/en not_active Ceased
- 2022-12-20 EP EP22912656.0A patent/EP4452954A2/en active Pending
- 2022-12-20 CN CN202280092041.0A patent/CN118765273A/zh active Pending
- 2022-12-20 AU AU2022419564A patent/AU2022419564A1/en active Pending
- 2022-12-20 TW TW111149059A patent/TW202333799A/zh unknown
- 2022-12-21 AR ARP220103534A patent/AR128052A1/es unknown
-
2024
- 2024-06-18 CL CL2024001832A patent/CL2024001832A1/es unknown
- 2024-06-28 CO CONC2024/0008733A patent/CO2024008733A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025500944A5 (https=) | ||
| JP2020518674A5 (https=) | ||
| RU2019139434A (ru) | Моноклональные антитела против igf-1r и их применение | |
| RU2019139432A (ru) | Фармакокинетическая оптимизация бифункциональных хелатов и их применение | |
| JP2007528372A (ja) | 多特異性抗体との使用のための治療および診断用コンジュゲート | |
| JP2014507400A (ja) | Ｎｏｔａによって錯体化されたアルミニウム−［１８ｆ］フッ化物で標識されたｈｅｒ２結合ペプチド | |
| JP2024503924A5 (https=) | ||
| JP2023076712A (ja) | 放射標識生体分子およびその使用 | |
| KR20220083768A (ko) | 방사성 금속 표지 항체의 제조 방법 | |
| JP2024523344A (ja) | 生物製剤を複数のキレーターと組み合わせるための方法及び材料 | |
| US20250121104A1 (en) | Egfr-cmet-targeted compounds and uses thereof | |
| JP2024519970A (ja) | 三価放射性同位体生物標的放射性医薬品、調製方法及び使用 | |
| WO2023033022A1 (ja) | 脱グリコシル化抗体の放射性複合体、及び、放射性医薬 | |
| EP4423137A1 (en) | Claudin 18.2-targeted compounds and uses thereof | |
| WO2023277144A1 (ja) | Ｈｅｇ１タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体 | |
| CN118317796A (zh) | EGFRvIII靶向化合物及其用途 | |
| CN120129534A (zh) | 放射性药物组合物 | |
| TW202144008A (zh) | 標靶fgfr3之放射免疫結合物及其用途 | |
| US20240350682A1 (en) | Steap2-targeted compounds and use thereof | |
| WO2022211051A1 (ja) | 抗ｅｇｆｒ抗体の放射性複合体、及び、放射性医薬 | |
| WO2025065045A1 (en) | Novel therapeutic targets | |
| WO2022224980A1 (ja) | 抗ｃｄ２０抗体の放射性複合体、及び、放射性医薬 | |
| WO2023157822A1 (ja) | 抗ｖｅｇｆ抗体の放射性複合体、及び、放射性医薬 |